Moderna Q1: COVID-19 vaccine sales and Biologics License App

Moderna Q1: COVID-19 vaccine sales and Biologics License Application submission


Moderna has reported the first profitable quarter in the company’s history: after 10 years of research and several billion dollars of investment in its mRNA platform. The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month.
Total revenue for the company was $1.9bn in Q1 (three months ended March 31, 2021): compared to $8m for the same period in 2020. Net income was $1.2bn for the quarter, compared to a net loss of $124m the year before.
Sales for 2021 are projected to total $19.2 billion. 
And looking forward, Moderna predicts that 2022 COVID-19 vaccine sales will exceed 2021’s sales.

Related Keywords

South Africa , United States , Israel , Switzerland , Brazil , America , , Pfizer , Purchase Agreements , Middle East , Latin America , Receptor Binding Domain , N Terminal Domain , ஒன்றுபட்டது மாநிலங்களில் , இஸ்ரேல் , சுவிட்சர்லாந்து , பிரேசில் , அமெரிக்கா , ஃபைசர் , நடுத்தர கிழக்கு , லத்தீன் அமெரிக்கா , ஏற்பி பிணைப்பு களம் , ச்சனியான முனையத்தில் களம் ,

© 2025 Vimarsana